Hemostemix Inc. (CVE:HEM – Get Free Report) rose 26.8% during trading on Thursday . The stock traded as high as C$0.36 and last traded at C$0.36. Approximately 1,397,556 shares traded hands during trading, an increase of 107% from the average daily volume of 673,541 shares. The stock had previously closed at C$0.28.
Hemostemix Price Performance
The company has a market cap of C$32.67 million, a PE ratio of -18.75 and a beta of 0.20. The stock’s 50-day moving average is C$0.13 and its 200 day moving average is C$0.09.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- How to Find Undervalued Stocks
- Bloom Energy: Powering the Future With Decentralized Energy
- How to Invest in Blue Chip Stocks
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- Technology Stocks Explained: Here’s What to Know About Tech
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
